Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To compare the long-term efficacy of initiating therapy with metformin/pioglitazone/exenatide in patients with new-onset type 2 diabetes mellitus (T2DM) versus sequential addition of metformin followed by glipizide and insulin. RESEARCH DESIGN AND METHODS: Drug-naive patients (N = 318) with new-onset T2DM were randomly assigned to receive for 3 years either 1) combination therapy with metformin, pioglitazone, and exenatide (triple therapy) or 2) sequential addition of metformin followed by glipizide and insulin (conventional therapy) to maintain HbA1c at <6.5% (48 mmol/mol). Insulin sensitivity and β-cell function were measured at baseline and 3 years. The primary outcome was the difference in HbA1c between the groups at 3 years. RESULTS: Baseline HbA1c ± SEM values were 9.0% ± 0.2% and 8.9% ± 0.2% in the triple therapy and conventional therapy groups, respectively. The decrease in HbA1c resulting from triple therapy was greater at 6 months than that produced by conventional therapy (0.30% [95% CI 0.21–0.39]; P = 0.001), and the HbA1c reduction was maintained at 3 years in patients receiving triple therapy compared with conventional therapy (6.4% ± 0.1% and 6.9% ± 0.1%, respectively), despite intensification of antihyperglycemic therapy in the latter. Thus, the difference in HbA1c between the two treatment groups at 3 years was 0.50% (95% CI 0.39–0.61; P < 0.0001). Triple therapy produced a threefold increase in insulin sensitivity and 30-fold increase in β-cell function. In conventional therapy, insulin sensitivity did not change and β-cell function increased by only 34% (both P < 0.0001 vs. triple therapy). CONCLUSIONS: Triple therapy with agents that improve insulin sensitivity and β-cell function in patients with new-onset T2DM produces greater, more durable HbA1c reduction than agents that lower glucose levels without correcting the underlying metabolic defects.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Acarbose has been shown to lower A1C and cause weight loss.1056,1057”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1056]
Citations
Cites
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621 · cited 2×
“OGTT-derived indices of insulin sensitivity and insulin secretion were calculated from the PG, insulin, and C-peptide (C-pep) concentrations during the OGTT, as previously described (5,20,21).”
MethodSelf-citationDormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129 · cited 1×
“95 SD) HbA1c difference between the two treatment arms based on the HbA1c decrease in the PROactive study (22).”
MethodDavies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Self-citationThe Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
Self-citationAhlqvist, E., Storm, P., Käräjämäki, A., Martinell, M., Dorkhan, M., Carlsson, A., Vikman, P., Prasad, R. B., Aly, D. M., Almgren, P., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30051-2 · Cited by 2,335
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192
Warram, J. H., Martin, B. C., Krolewski, A. S., Soeldner, J. S., & Kahn, C. R. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-12-909 · Cited by 1,038
Ferrannini, E., Gastaldelli, A., Miyazaki, Y., Matsuda, M., Mari, A., & DeFronzo, R. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1133 · Cited by 540
Self-citationAbdul-Ghani, M. A., Jenkinson, C. P., Richardson, D. K., Tripathy, D., & DeFronzo, R. A. (2006) · Diabetes · doi:10.2337/db05-1200 · Cited by 500
Self-citation
Cited by
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Self-citationSamson, S. L., Vellanki, P., Blonde, L., Christofides, E. A., Galindo, R. J., Hirsch, I. B., Isaacs, S. D., Izuora, K. E., Low Wang, C. C., Twining, C. L., et al. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.02.001 · Cited by 375
Sibony, R. W., Segev, O., Dor, S., & Raz, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417147 · Cited by 167
Managing insulin resistance: the forgotten pathophysiological component of type 2 diabetes
Abdul-Ghani, M. A., Maffei, P., & DeFronzo, R. A. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00127-x · Cited by 89
Self-citationAn Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes
Giglio, R. V., Παπάνας, Ν., Rizvi, A. A., Ciaccio, M., Patti, A. M., Ilias, Ι., Stoian, A. P., Sahebkar, A., Janež, A., & Rizzo, M. (2022) · Medicina · doi:10.3390/medicina58101475 · Cited by 80
Lavynenko, O., Abdul‐Ghani, M., Alatrach, M., Puckett, C., Adams, J., Abdelgani, S., Alkhouri, N., Triplitt, C., Clarke, G. D., Vasquez, J. A., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14650 · Cited by 44
Self-citationType 2 diabetes in South Asians
Misra, A., Sattar, N. A., Ghosh, A., Nassar, M., Jayawardena, R., & Gupta, R. (2025) · BMJ · doi:10.1136/bmj-2024-079801 · Cited by 48
“There is some evidence that simultaneously targeting different pathways that lead to hyperglycemia achieves better control, 114 but the durability and costs of this approach need further analysis, especially in low and middle income countries.”
Ku, E. J., Lee, D., Jeon, H. J., & Oh, T. K. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109123 · Cited by 38
Initial Combination Therapy in Type 2 Diabetes
Kim, J. Y., & Kim, N. H. (2023) · Endocrinology and Metabolism · doi:10.3803/enm.2023.1816 · Cited by 47
“[36].”
BackgroundMethodInfluentialNicchio, I. G., Cirelli, T., Quil, L. C. D. C., Camilli, Â. C., Scarel‐Caminaga, R. M., & Leite, F. R. M. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116908 · Cited by 29
Samson, S. L., Vellanki, P., Blonde, L., Hirsch, I. B., Hoang, T. D., Isaacs, S. D., Izuora, K. E., Wang, C. C. L., Ooi, C. P., Padilla, B. I., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.006 · Cited by 35
Liu, L., Ke, W., Li, H., Li, F., Fan, G., Kuang, J., Ma, J., Zhang, X., Ji, B., Li, S., et al. (2024) · BMJ · doi:10.1136/bmj-2024-080122 · Cited by 23
Pioglitazone in diabetic kidney disease: forgotten but not gone
Papaetis, G. S. (2022) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad/151046 · Cited by 17
“Early intensive triple therapy with MET, PIO and exenatide was shown to produce greater and more durable A1C reductions in patients with new-onset T2D compared to sequential add-on therapy with MET followed by SU and then basal insulin; patients treated with triple combination therapy experienced less hepatic steatosi…”
ResultAWARE A novel web application to rapidly assess cardiovascular risk in type 2 diabetes mellitus
Berra, C., Manfrini, R., Mirani, M., Bucciarelli, L. G., Zakaria, A. S., Piccini, S., Ghelardi, R., Lunati, M. E., Geloneze, S. R., Bifari, F., et al. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02115-x · Cited by 16
Kim, N. H., Moon, J. S., Lee, Y., Cho, H., Kwak, S. H., Lim, S. K., Moon, M. K., Kim, D., Kim, T. H., Ko, E., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15705 · Cited by 17
Papaetis, G. S., Picolos, M. K., & Sacharidou, A. (2025) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad/202298 · Cited by 14
Allamreddy, S. R., Arora, M., Ganugula, R., Friend, R., Basu, R., & Kumar, M. N. V. R. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.001074 · Cited by 12
Lee, C., Lui, D. T. W., Mak, L., Fong, C. H.-Y., Chan, K. S., Mak, J. H., Cheung, C. Y. Y., Chow, W., Woo, Y. C., Yuen, M., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16049 · Cited by 12
“20 Indeed, following the results of studies such as VERIFY, DURATION-8 and EDICT, 21 – 23 professional guidelines suggested to consider early upfront combination of antidiabetic agents in patients who had high HbA1c at diagnosis, young patients and/or those need timely cardio-kidney protection…”
Bell, D. S. H. (2022) · Journal of Diabetes Research · doi:10.1155/2022/7787732 · Cited by 12
“This combination not only produces a greater reduction of HbA1c but also a more durable HbA1c reduction [14].”
BackgroundLee, J., & Cho, J. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0078 · Cited by 12
“Although previous studies have suggested the potential benefit of early intensive glucose-lowering therapy, most of the current practice guidelines recommend serial escalation of diabetic medications in patients with newly diagnosed diabetes unless those patients are severely hyperglycemic [6,7].”
BackgroundDas, A. K., Saboo, B., Chawla, R., Aravind, S. R., Rajput, R., Singh, A. K., Mukherjee, J. J., Jhingan, A. K., Shah, P., Deshmukh, V. C., et al. (2023) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-023-01192-6 · Cited by 18
“Evidence suggests that in new-onset T2DM, triple therapy with antidiabetic drugs that enhance insulin sensitivity and beta-cell function led to a higher and more long-lasting reduction in HbA1c than treatment that only lowered glucose levels without addressing the underlying metabolic issues [60].”
BackgroundAbdul‐Ghani, T., PUCKETT, C. L., Migahid, O., Abdelgani, S., Migahed, A., Adams, J. M., Triplitt, C. L., DeFronzo, R. A., Jayyousi, A., & Abdul‐Ghani, M. A. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14767 · Cited by 10
Self-citationTreatment adherence and the contemporary approach to treating type 2 diabetes mellitus
Kolarš, B., Minaković, I., Grabovac, B., Živanović, D., & Mijatović, V. (2024) · Biomedical Papers · doi:10.5507/bp.2024.009 · Cited by 13
Schwartz, S. S., Corkey, B. E., Gavin, J. R., DeFronzo, R. A., & Herman, M. E. (2024) · BMC Medicine · doi:10.1186/s12916-024-03518-5 · Cited by 12
Self-citationIncorporating Evidence and Guidelines for Personalized Care of Diabetes and Chronic Kidney Disease
Neumiller, J. J., Alicic, R. Z., & Tuttle, K. R. (2023) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2023.151427 · Cited by 10
Anson, M., Malik, A. I., Zhao, S. S., Austin, P. J., Hernández, G., Jaffar, S. S., Garrib, A. V., Cuthbertson, D. J., & Alam, U. (2024) · Journal of Diabetes Research · doi:10.1155/2024/3470654 · Cited by 11
“A 3-year follow-up of EDICT highlighted a threefold increase in insulin sensitivity, a thirtyfold increase in β cell function, and durability of HbA1c reduction in the triple therapy arm compared to the conventional group, despite the escalation of treatment in the latter [16].”
BackgroundInsulin Secretion Predicts the Response to Antidiabetic Therapy in Patients With New-onset Diabetes
Abdelgani, S., PUCKETT, C. L., Adams, J. M., Triplitt, C. L., DeFronzo, R. A., & Abdul‐Ghani, M. A. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab403 · Cited by 8
Self-citationFrom Glucose Control to Multifaceted Benefits: The Rise of Modern Sulphonylureas in Diabetes Care
Shrestha, D., Dhingra, A., Shakya, S., & Tuladhar, J. (2025) · Current Diabetes Reports · doi:10.1007/s11892-025-01582-6 · Cited by 8
“…indicates that in new-onset T2DM, a triple-drug regimen with antidiabetic agents that boosts insulin sensitivity and β-cell function causes a greater and better long-lasting decline in HbA1c than therapy that only lowers glucose levels without managing the underlying metabolic problems [42].”
Gudoor, R., Suits, A., & Shubrook, J. H. (2023) · Diabetology · doi:10.3390/diabetology4030032 · Cited by 8
Schwartz, S. S., & Herman, M. E. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1394805 · Cited by 6
Abdelgani, S., PUCKETT, C. L., Adams, J. M., Triplitt, C. L., DeFronzo, R. A., & Abdul‐Ghani, M. A. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14383 · Cited by 6
Self-citationAbdul‐Ghani, M. A., PUCKETT, C. L., Abdelgani, S., Merovci, A., Lavrynenko, O., Adams, J. M., Triplitt, C. L., & DeFronzo, R. A. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-004981 · Cited by 6
“…plus exenatide on liver fat content and carotid intima– media thickness (cIMT) in participants of the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT) study 8 who maintained optimal glycemic control, that is, HbA1c 6.5% through the entire study duration (6 years).”
InfluentialSelf-citationPersonalized approach for type 2 diabetes pharmacotherapy: where are we and where do we need to be?
Abdul‐Ghani, M. A., & DeFronzo, R. A. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1967319 · Cited by 5
“demonstrated that, although on mean the HbA1c increased progressively over time in metformin-treated patients, in approximately one-quarter of patients, the HbA1c remained stable for 3 years [109].”
BackgroundMethodSelf-citationSuits, A., Gudoor, R., & Shubrook, J. H. (2023) · Diabetology · doi:10.3390/diabetology4010011 · Cited by 5
“Patients on triple therapy had sig ificantly lower fr quency of hypoglycemic ev nts, and the most common adv rse effect was mild nausea [36].”
BackgroundSeidu, S., Almaqhawi, A., Abdool, M., Kunutsor, S. K., Davies, M. J., & Khunti, K. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14715 · Cited by 4
“The finding of a reduced risk of hypoglycaemia associated with the initial combination therapy (based on two RCTs and a single observational cohort) needs to be interpreted with caution, given that the stepwise approach arm in two of the studies included antidiabetic therapies associated with an increased risk of hypo…”
BackgroundXu, L., Liu, L., Xie, Z., Huang, Z., Li, H., Liu, J., He, X., Deng, W., & Li, Y. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70135 · Cited by 2
“…influenced to advocate early more intensive glucose-lowering therapy, such as dual combination therapies of vildagliptin plus metformin in VERIFY (Vildagliptin Efficacy in combination with metfoRmIn For earlY treatment of type 2 diabetes), than the traditional step-wise add-on strategy [28–30].”
The world congress on insulin resistance, diabetes, and cardiovascular disease ( WCIRDC )
Bloomgarden, Z. T. (2022) · Journal of Diabetes · doi:10.1111/1753-0407.13260 · Cited by 2
“In the study, approximately one quarter of those randomized to metformin alone had sustained stable glycemic control with metformin, with Abdul-Ghani showing evidence that these were the patients with higher baseline levels of beta-cell function, as measured using the ratio of C-peptide levels before to that 120 min a…”
BackgroundPioglitazone: Reviewed and Renewed
Charbonneau, M. S., & Capoccia, K. L. (2022) · ADCES in Practice · doi:10.1177/2633559x221093294 · Cited by 2
Expert Consensus Statement on Simplified Glycemic Care in Patients With Type 2 Diabetes Mellitus
Sethi, B. K., Chowdhury, S., Jain, S. M., Zargar, A. H., Chadha, M. D., Bhattacharyya, A., Shaikh, S. S., Makkar, B. M., Chawla, M. S., Kalra, P., et al. (2025) · Cureus · doi:10.7759/cureus.87002 · Cited by 1
Complex metabolic–endocrine syndromes: associations with cardiovascular disease
Krentz, A. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00010-3 · Cited by 2
Manjula, S. N., & Krishna Kumar, M. (2024) · South Asian Research Journal of Medical Sciences · doi:10.36346/sarjms.2024.v06i01.003 · Cited by 1
“The combination therapy has several potential advantages, including increased duration of the glycemic effect, simultaneous targeting of the multiple pathophysiological processes and complementary clinical benefits (e.g., on glycemic control, weight and cardiovascular risk profiles) [6].”
BackgroundBeitelshees, A. L., Streeten, E. A., Yazdi, Z. S., Whitlatch, H. B., Mitchell, B. D., Shuldiner, A. R., Montasser, M. E., & Taylor, S. I. (2024) · Clinical and Translational Science · doi:10.1111/cts.13809 · Cited by 2
“1,3,21,22 While one could add a DPP4 inhibitor for all when it becomes inexpensive enough, some patients will have a very limited HbA1c response leading to prolonged uncontrolled diabetes.”
Bailey, C. J., & Krentz, A. J. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch35 · Cited by 2
Park, Y.-H., Sohn, M., & Lim, S. K. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0485 · Cited by 5
AWARE. A web application to rapidly assess cardiovascular risk in Type 2 Diabetes Mellitus.Preprint
Berra, C., Manfrini, R., Mirani, M., Bucciarelli, L. G., Zakaria, A. S., Piccini, S., Ghelardi, R., Lunati, M. E., Geloneze, S. R., Bifari, F., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2134695/v1
AWARE. A web application to rapidly assess cardiovascular risk in Type 2 Diabetes Mellitus.Preprint
Berra, C., Manfrini, R., Mirani, M., Bucciarelli, L. G., Zakaria, A. S., Piccini, S., Ghelardi, R., Lunati, M. E., Geloneze, S. R., Bifari, F., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2134695/v2
Initiale Kombitherapie: Pro & Kontra
Meißner, T. (2023) · Info Diabetologie · doi:10.1007/s15034-023-4552-z
Simplicity: The Ultimate Sophistication in Managing Type 2 Diabetes With Severe Hyperglycemia
Liu, L., & Li, Y. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.70042
3. Blood glucose-lowering therapies – Non-insulin options for type 2 diabetes
Colagiuri, S., & Ceriello, A. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112147 · Cited by 1
Liu, M., Xie, S., Kong, Y., Yang, Y., Chen, R., Wang, Y., Cao, S., & Song, Y. (2025) · Stem Cells International · doi:10.1155/sci/2681413
“Although pharmacological and other adjuvant treatments can make patients ’ blood glucose levels approach the normal range as much as possible [17], thereby delaying or even preventing the occurrence of diabetes-related complications [18].”
Demidova, T. Y., & Belolipetsky, Y. A. (2025) · FOCUS Endocrinology · doi:10.62751/2713-0177-2025-6-4-10 · Cited by 1
Early combination therapy in type 2 diabetes: Rethinking initial treatment strategies
Janež, A., Smid, T., Rizzo, M., & Tankova, T. I. (2026) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2026.109392
Abdul‐Ghani, M. A., Abu‐Farha, M., Puckett, C., Abdul‐Ghani, T., Baskoy, G., Abdelgani, S., Zaitoon, H., Merovci, A., Adams, J., Triplitt, C., et al. (2026) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2026-006294
Self-citation
Metadata
- Authors
- Abdul-Ghani, M., Puckett, C., Adams, J., Khattab, A., Baskoy, G., Cersosimo, E., Triplitt, C., & DeFronzo, R. A.
- Affiliations
- Division of Diabetes, University of Texas Health Science Center and Texas Diabetes Institute, San Antonio, TX
- The University of Texas at San Antonio Health Science Center (US)
- Corresponding author
- DeFronzo, Ralph A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-12-03
- Volume
- 44
- Issue
- 2
- Pages
- 433-439
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC7818318
- OpenAlex
- W3107469749
- Cited by
- 55
- References
- 26
- Citations by year
- 2026: 3 · 2025: 10 · 2024: 14 · 2023: 10 · 2022: 13 · 2021: 5
- FWCI
- 5.28
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (R01DK24092-34)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- triple combination therapy, metformin, pioglitazone, exenatide, glipizide, insulin therapy, HbA1c reduction, insulin sensitivity, beta-cell function, antihyperglycemic therapy
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Metformin, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.